Stock Analysis
Illumina IncILMN
P/E 48.11×· 5Y range 11.53–86.01×· 56th percentile of history
Sector: Technology · Industry: Laboratory Analytical Instruments
AnalystsBuy28 analystsP/E 48.1× sits at the 56th percentile of its 5.086926762491444-year history.
Cash covers 8% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Profitability77
- Quality70
Risks
- Growth24
Mixed picture — no clear quality or value edge.
Market context
-2.0% today· Z 1.3σ
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 7.4 — safe-zone balance sheet
- ✓ROE 30.3% — efficient capital deployment
What's happening with ILMN
Profile
Strong profitability; growth and valuation lag behind.
How is each axis scored?
- Valuation29/100 · Weak
- P/E vs own history (56th pct)12/25
- FCF yield (2.4%)5/25
- P/S (8.7x)12/25
- EV/EBIT (46.8x)0/25
- Growth24/100 · Weak
- Revenue CAGR (-1.0%)0/25
- Net income CAGR (2.8%)6/25
- EPS CAGR 5Y (1.9%)6/25
- Fwd implied growth (12.4%)12/25
- Profitability77/100 · Strong
- ROIC (13.8%)12/25
- ROE (30.3%)25/25
- Net margin (18.3%)20/25
- Operating margin (19.6%)20/25
- Financial Health55/100 · Moderate
- Altman Z (7.44)25/25
- Current ratio (2.08)25/25
- Interest coverage (-6.2x)0/25
- Net cash / debt (D/A 35%)5/25
- Quality70/100 · Moderate
- Piotroski F (8/9)25/25
- Beneish M (-2.45)20/25
- FCF conversion (113%)25/25
- Margin stability (σ 27.4%)0/25
- Moat63/100 · Moderate
- ROIC >12% years (6/10 yrs)13/25
- Median gross margin (67.2%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -96.1%)0/25
Risk Flags
- ⚠SBC 5.9% of revenue — real dilution cost
- ⚠3 loss-making years in recent history
- ⚠Interest coverage -6.2× — thin debt cushion
- ⚠Revenue shrinking 1.0%/yr
About Illumina Inc
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Show more
The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Headquarters: SAN DIEGO, CA · Employees: 8,650 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
29EP/E (TTM)47.3xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 11.5x–86.0x · 56th pct
P/FCF43.1xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.4%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -0.2%–7.8% · 69th pct
P/S (TTM)8.67xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.6x–16.7x · 86th pct
EV/EBIT46.8xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 31.5x–52.3x · 85th pct
EV/Sales9.1xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E42.1xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio14.31xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio4.18D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
77B+ROIC13.8%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE30.3%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA12.7%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin18.3%A
Grade A: HighNet Income / Revenue
Operating Margin19.6%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin66.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin20.7%A
Grade A: HighFCF / Revenue
True FCF Margin14.8%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
24ERevenue CAGR-1.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR2.8%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)1.9%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth12.4%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+2.7%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income32.3%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue5.9%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
55CAltman Z-Score7.44A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.08xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.25xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-6.2xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment2.5yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT2.6xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.94xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.08xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
70B+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.45A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion113.0%A
Grade A: StrongFCF / Net Income
Margin Stability27.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue3.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.69xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Thaysen Jacob Filed | Thaysen Jacob | Tax withholding | -1303 | |
Meister Keith A. Filed | Meister Keith A. | Grant / award | +107 | |
Ullem Scott B. Filed | Ullem Scott B. | Grant / award | +113 | |
Coletti Julie Ann Filed | Coletti Julie Ann | Grant / award | +5.3K | |
Coletti Julie Ann Filed | Coletti Julie Ann | Grant / award | +14.2K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Coletti Julie Ann Filed | Coletti Julie Ann | Grant / award | +4.5K | |
Barnard Steven Filed | Barnard Steven | Tax withholding | -408 | |
Meister Keith A. Filed | Meister Keith A. | SellOpen market sale | -11351 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
63BROIC >12% Years6/10 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)67.2%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-96.1%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$5.46
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$7.74
Cash & short-term investments per share (Finnhub)
Book Value / Share$18.79
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.55B
Total debt obligations (short + long term)
Cash & Equiv.$215.00M
Cash and short-term investments
Net Debt$2.34B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.72B
Shareholders' equity (book value)
Asset / Liability1.69xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$38.96B
Current Market Capitalization
Beta1.43C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Illumina Inc (ILMN)
ILMN is down 2.01% at the last close. Illumina Inc meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 7.44 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.45 suggests a low likelihood of earnings manipulation. Revenue has been contracting (CAGR ≈ -1%), which weighs on the growth outlook. Illumina Inc converts about 21% of revenue into free cash flow — strong cash generation.
- Takes ~2.5 years to repay net debt from free cash flow.
- Interest coverage of -6.2× leaves little room for earnings shocks.
- Illumina Inc posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 29/100, ILMN trades at a premium to its historical multiples (P/E 47.3).
- Return on equity of 30.3% is well above the market average.
See how ILMN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ILMN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | Regular | 274.24 | -6.62% | -2.55 |
| Oct 6 | After-hours | 273.00 | -7.04% | -2.68 |
Frequently Asked Questions about ILMN
What is the current Illumina Inc (ILMN) stock price?
ILMN is trading at $262.54 at the last market close, down 2.01% on the session. PreMarketPrice tracks ILMN pre-market, intraday and after-hours prices.
Is ILMN stock a buy right now?
PreMarketPrice's quantitative model rates Illumina Inc's financial health at 55/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ILMN stock overvalued?
Illumina Inc trades at a trailing P/E of 47.3 and our valuation score rates it 29/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Illumina Inc report earnings?
No confirmed earnings date is currently scheduled for ILMN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Illumina Inc operate in?
Illumina Inc operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does Illumina Inc do?
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications.
About Illumina Inc (ILMN) Stock
Illumina Inc (ILMN) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. As of the latest update, Illumina Inc is trading at $262.54, down 2.01% on the day with a market capitalization of $39.0 billion. The financial health score for ILMN is 55/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ILMN stock.
ILMN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Illumina Inc (ILMN) across multiple dimensions:
- Pre-market price & movement: Real-time ILMN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ILMN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Illumina Inc across multiple reporting periods.
- Financial health score: A composite score of 55/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ILMN.
- Sector peers: Compare ILMN against 6 other technology stocks on key financial metrics.
Is ILMN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Illumina Inc (ILMN) as an investment. The financial health score of 55/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Illumina Inc (ILMN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.